Values First Advisors
COLL icon

Values First Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Values First Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$384K Sell
17,593
-420
-2% -$12.3K 0.18% 127
2026
Q2 		$652K Buy
18,013
+927
+5% +$31.7K 0.3% 97
2026
Q1 		$565K Buy
17,086
+83
+0.5% +$3.51K 0.29% 92
2025
Q4 		$787K Sell
17,003
-582
-3% -$24.4K 0.41% 75
2025
Q3 		$615K Sell
17,585
-864
-5% -$30K 0.33% 83
2025
Q2 		$546K Buy
18,449
+1,804
+11% +$51.5K 0.3% 98
2025
Q1 		$497K Sell
16,645
-261
-2% -$7.98K 0.29% 95
2024
Q4 		$484K Sell
16,906
-1,506
-8% -$49.8K 0.27% 97
2024
Q3 		$711K Buy
18,412
+1,419
+8% +$50.6K 0.39% 69
2024
Q2 		$547K Buy
16,993
+1,057
+7% +$36.6K 0.33% 78
2024
Q1 		$619K Sell
15,936
-17,929
-53% -$627K 0.36% 78
2023
Q4 		$1.04M Sell
33,865
-9,642
-22% -$242K 0.63% 47
2023
Q3 		$972K Buy
43,507
+6,557
+18% +$150K 0.63% 46
2023
Q2 		$794K Buy
36,950
+7,325
+25% +$166K 0.48% 62
2023
Q1 		$711K Sell
29,625
-18,003
-38% -$477K 0.45% 65
2022
Q4 		$1.1M Buy
47,628
+2,193
+5% +$44.2K 0.77% 44
2022
Q3 		$728K Sell
45,435
-2,652
-6% -$46.8K 0.52% 64
2022
Q2 		$852K Buy
48,087
+2,474
+5% +$41.6K 0.61% 54
2022
Q1 		$929K Buy
45,613
+3,301
+8% +$62.4K 0.59% 54
2021
Q4 		$790K Buy
42,312
+539
+1% +$10.5K 0.47% 70
2021
Q3 		$825K Buy
41,773
+4,551
+12% +$98.4K 0.53% 63
2021
Q2 		$880K Buy
37,222
+4,325
+13% +$100K 0.6% 58
2021
Q1 		$780K Sell
32,897
-6,142
-16% -$146K 0.58% 62
2020
Q4 		$782K Buy
39,039
+7,798
+25% +$152K 0.62% 57
2020
Q3 		$650K Buy
31,241
+6,932
+29% +$125K 0.6% 58
2020
Q2 		$425K Sell
24,309
-36
-0.1% -$705 0.42% 82
2020
Q1 		$398K Sell
24,345
-15,254
-39% -$315K 0.48% 68
2019
Q4 		$815K Buy
+39,599
New +$660K 0.79% 49

Other funds holding COLL

Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Kendall Capital Management
Kendall Capital Management Rockville, Maryland $605M AUM 38.16% 1-Year Est. Return
SummerHaven Investment Management
SummerHaven Investment Management Stamford, Connecticut $179M AUM 57.61% 1-Year Est. Return
Verdence Capital Advisors
Verdence Capital Advisors Hunt Valley, Maryland $2.35B AUM 27.25% 1-Year Est. Return
Smith Group Asset Management
Smith Group Asset Management Dallas, Texas $1.53B AUM 46.79% 1-Year Est. Return

Values First Advisors's COLL Position: Q3 2026 in Review

Values First Advisors reduced its Collegium Pharmaceutical (COLL) stake by 2.3% in Q3 2026, selling an estimated $12.3K and leaving 17,593 shares worth $384K. The position accounts for 0.18% of the portfolio, ranked #127.

Values First Advisors first reported a position in COLL in Q4 2019 and has held it in 28 quarters since. The position peaked at $1.1M in Q4 2022. 43 funds tracked by Wall St. Rank hold COLL as of Q3 2026.

  • Values First Advisors held 17,593 shares of Collegium Pharmaceutical worth $384K as of Q3 2026.
  • Values First Advisors sold 420 Collegium Pharmaceutical shares in Q3 2026, an estimated $12.3K.
  • Collegium Pharmaceutical made up 0.18% of Values First Advisors's portfolio in Q3 2026, its #127 holding.
  • Values First Advisors first reported a position in Collegium Pharmaceutical in Q4 2019 and has held it in 28 quarters since.
  • Values First Advisors's Collegium Pharmaceutical position peaked at $1.1M in Q4 2022.
  • 43 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2026.

Based on Values First Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.